DK3773689T5 - Antigene peptider til forebyggelse og behandling af kræft - Google Patents

Antigene peptider til forebyggelse og behandling af kræft Download PDF

Info

Publication number
DK3773689T5
DK3773689T5 DK19716176.3T DK19716176T DK3773689T5 DK 3773689 T5 DK3773689 T5 DK 3773689T5 DK 19716176 T DK19716176 T DK 19716176T DK 3773689 T5 DK3773689 T5 DK 3773689T5
Authority
DK
Denmark
Prior art keywords
cancer
prevention
treatment
antigenic peptides
antigenic
Prior art date
Application number
DK19716176.3T
Other languages
English (en)
Other versions
DK3773689T3 (da
Inventor
Laurent Chene
Francesco Strozzi
Christophe Bonny
Original Assignee
Enterome S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterome S A filed Critical Enterome S A
Publication of DK3773689T3 publication Critical patent/DK3773689T3/da
Application granted granted Critical
Publication of DK3773689T5 publication Critical patent/DK3773689T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001119—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK19716176.3T 2018-04-11 2019-04-11 Antigene peptider til forebyggelse og behandling af kræft DK3773689T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305444 2018-04-11
EP2018077512 2018-10-09
PCT/EP2019/059329 WO2019197567A2 (en) 2018-04-11 2019-04-11 Antigenic peptides for prevention and treatment of cancer

Publications (2)

Publication Number Publication Date
DK3773689T3 DK3773689T3 (da) 2023-01-16
DK3773689T5 true DK3773689T5 (da) 2024-08-19

Family

ID=66092357

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19716176.3T DK3773689T5 (da) 2018-04-11 2019-04-11 Antigene peptider til forebyggelse og behandling af kræft

Country Status (19)

Country Link
US (2) US12016910B2 (da)
EP (2) EP4169528A1 (da)
JP (2) JP7384819B2 (da)
CN (2) CN120535570A (da)
AU (1) AU2019253217B2 (da)
BR (1) BR112020020780A2 (da)
CA (1) CA3094262A1 (da)
DK (1) DK3773689T5 (da)
ES (1) ES2935702T3 (da)
FI (1) FI3773689T3 (da)
HR (1) HRP20230007T1 (da)
HU (1) HUE060791T2 (da)
LT (1) LT3773689T (da)
MX (2) MX2020010701A (da)
PL (1) PL3773689T3 (da)
RS (1) RS63873B1 (da)
SI (1) SI3773689T1 (da)
SM (1) SMT202300021T1 (da)
WO (1) WO2019197567A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
CN110049774A (zh) 2016-10-07 2019-07-23 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
IL302345B2 (en) 2016-10-07 2024-12-01 Enterome S A Immunogenic compounds for cancer therapy
CN110022894B (zh) 2016-10-07 2024-01-19 恩特罗姆公司 用于癌症疗法的免疫原性化合物
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
WO2021074389A1 (en) * 2019-10-16 2021-04-22 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
LT4021487T (lt) * 2019-11-15 2024-02-12 Enterome S.A. Antigeniniai peptidai, skirti b-ląstelių piktybinių navikų prevencijai ir gydymui
CN111197040B (zh) * 2020-01-21 2023-08-08 福建亿彤生物科技有限公司 壳多糖酶3样蛋白1（chi3l1）抗原表位肽、抗原、抗体、用途及试剂盒
CN114163513B (zh) * 2021-03-24 2025-02-25 深圳市新靶向生物科技有限公司 一种与肝癌驱动基因突变相关的抗原肽组合及其应用
CN119522232A (zh) * 2022-03-31 2025-02-25 恩特姆生物科学公司 用于预防和治疗癌症的抗原肽
IT202200006785A1 (it) * 2022-04-06 2023-10-06 Istituto Naz Tumori Irccs Fondazione G Pascale Analoghi di antigeni tumorali da microbiota e usi relativi
US20260041748A1 (en) * 2022-07-29 2026-02-12 Lg Chem, Ltd. Recombinant fusion protein for antigen delivery and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
JP2003535024A (ja) 1999-06-29 2003-11-25 エピミューン インコーポレイテッド Ｈｌａ結合ペプチドおよびそれらの使用
FR2798128B1 (fr) 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
CA2400215A1 (en) 2000-02-23 2001-08-30 Epimmune Inc. Hla binding peptides and their uses
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
EP1496923A4 (en) 2002-03-22 2005-10-19 Penn State Res Found IMMUNOTHERAPY AGAINST CANCER
US20060079453A1 (en) 2002-10-03 2006-04-13 John Sidney Hla binding peptides and their uses
CN1954217B (zh) 2004-02-06 2013-05-08 国立健康与医学研究所 衍生自gp41的多肽、含有所述多肽的疫苗组合物以及用于治疗个体HIV病毒感染的用途
US20120052080A1 (en) 2004-09-21 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
WO2008073463A2 (en) 2006-12-11 2008-06-19 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
MX2010002002A (es) 2007-08-20 2010-03-11 Oncotherapy Science Inc Peptido foxm1 y agente medicinal que lo contiene.
RS53872B2 (sr) 2008-05-14 2018-06-29 Immatics Biotechnologies Gmbh Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
EP2324057B1 (en) 2008-08-12 2018-03-21 MSD Italia S.r.l. Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
TWI469791B (zh) * 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
WO2010129033A2 (en) 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
WO2011055980A2 (ko) 2009-11-03 2011-05-12 고려대학교 산학협력단 산화아연-결합성 펩타이드를 포함하는 단백질과 산화아연 나노입자의 복합체 및 그의 용도
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
WO2011140284A2 (en) 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2013101690A1 (en) 2011-12-29 2013-07-04 modeRNA Therapeutics Modified mrnas encoding cell-penetrating polypeptides
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
EP3855184B1 (en) 2012-03-19 2023-12-27 Stemline Therapeutics Inc. Methods for treating and monitoring the status of cancer
US9428813B2 (en) 2012-03-26 2016-08-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
RS62406B1 (sr) 2012-05-16 2021-10-29 Stemline Therapeutics Inc Vakcine protiv kancera sa ciljanim delovanjem na matične ćelije kancera
US20140141044A1 (en) 2012-11-12 2014-05-22 Dana-Farber Cancer Institute, Inc. Cord Colitis Syndrome Pathogen
CA2893359C (en) 2012-12-05 2021-12-28 Strategia Therapeutics, Inc. Protein expression enhancing polypeptides
JP6548579B2 (ja) 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
CA2951325C (en) 2014-06-06 2023-09-12 Herlev Hospital Determining antigen recognition through barcoding of mhc multimers
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
CN108026513A (zh) 2015-03-31 2018-05-11 新加坡科技研究局 树突状细胞的抗原加载的方法和疫苗
JP6873482B2 (ja) * 2015-10-08 2021-05-19 オンコセラピー・サイエンス株式会社 Ｆｏｘｍ１由来ペプチドおよびそれを含むワクチン
EP3464630A1 (en) 2016-05-23 2019-04-10 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Methods of diagnosing cancer using cancer testis antigens
CN110049774A (zh) 2016-10-07 2019-07-23 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
IL302345B2 (en) 2016-10-07 2024-12-01 Enterome S A Immunogenic compounds for cancer therapy
CN110022894B (zh) 2016-10-07 2024-01-19 恩特罗姆公司 用于癌症疗法的免疫原性化合物
JP7232825B2 (ja) 2017-10-09 2023-03-03 エンテローム エスエー 腫瘍関連抗原エピトープの微生物叢（ｍｉｃｒｏｂｉｏｔａ）配列変異体
WO2019197563A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
WO2021074389A1 (en) 2019-10-16 2021-04-22 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
LT4021487T (lt) 2019-11-15 2024-02-12 Enterome S.A. Antigeniniai peptidai, skirti b-ląstelių piktybinių navikų prevencijai ir gydymui

Also Published As

Publication number Publication date
HUE060791T2 (hu) 2023-04-28
FI3773689T3 (fi) 2023-01-31
RS63873B1 (sr) 2023-02-28
CN112118863A (zh) 2020-12-22
ES2935702T3 (es) 2023-03-09
AU2019253217B2 (en) 2025-09-25
US20210113678A1 (en) 2021-04-22
CN120535570A (zh) 2025-08-26
US12016910B2 (en) 2024-06-25
US20240293520A1 (en) 2024-09-05
PL3773689T3 (pl) 2023-03-13
CN112118863B (zh) 2025-05-30
SI3773689T1 (sl) 2023-02-28
EP4169528A1 (en) 2023-04-26
JP2021520818A (ja) 2021-08-26
JP7670445B2 (ja) 2025-04-30
AU2019253217A1 (en) 2020-10-15
LT3773689T (lt) 2023-01-25
BR112020020780A2 (pt) 2021-03-02
EP3773689A2 (en) 2021-02-17
SMT202300021T1 (it) 2023-03-17
JP7384819B2 (ja) 2023-11-21
DK3773689T3 (da) 2023-01-16
MX2020010701A (es) 2021-01-20
MX2023014457A (es) 2023-12-15
WO2019197567A3 (en) 2019-11-28
EP3773689B1 (en) 2022-11-09
CA3094262A1 (en) 2019-10-17
WO2019197567A2 (en) 2019-10-17
HRP20230007T1 (hr) 2023-03-03
JP2024016203A (ja) 2024-02-06

Similar Documents

Publication Publication Date Title
DK3773689T3 (da) Antigene peptider til forebyggelse og behandling af kræft
IL269150A (en) Compositions and methods for treating cancer
IL268814A (en) Compositions and methods for treatment of cancer
DK3826667T3 (da) Claudin6-antistoffer og fremgangsmåder til behandling af kræft
DK3735295T3 (da) Forbedrede peptidfarmaceutika til behandling af nash og andre lidelser
DK3445388T3 (da) Materialer og fremgangsmåder til behandling af hæmoglobinopatier
IL263224A (en) Methods and compositions for treating cancers
DK3455259T3 (da) Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling
DK3096798T3 (da) Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem
DK4021487T5 (da) Antigene peptider til forebyggelse og behandling af b-celle malignitet
IL268872A (en) Methods and compositions for treating cancers using antisense
IL269157A (en) Compositions and methods for treating cancer
IL283200A (en) Combination treatment of nafld and nash
ZA202007649B (en) Virus and antigen purification and conjugation
DK3773738T3 (da) Antistof-lægemiddelkonjugater og anvendelser deraf til behandling af cancer
DK3426777T3 (da) Kombinationsvektorer og fremgangsmåder til behandling af cancer
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK3778592T3 (da) PSMA-målrettet radiolægemiddel til diagnosticering og behandling af prostatacancer
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
IL281605A (en) B*44 restricted peptides for use in immunotherapy against cancers and related methods
DK3273986T3 (da) Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer
DK3293201T3 (da) Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer
IL282478A (en) Materials and methods for treating cancer
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3720879T3 (da) Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer